Seres Therapeutics, Inc. MCRB PHARMA

Q: What is the current share price of Seres Therapeutics, Inc. (MCRB)?

As of 2026-09-19 21:16 PDT, Seres Therapeutics, Inc. (MCRB) trades at $5.56 on NasdaqGS. Its 52-week range is $4.34 to $28.63.

Q: What is the market capitalisation of MCRB?

Seres Therapeutics, Inc. (MCRB) has a market capitalisation of $55.85M on NasdaqGS.

Q: What is the P/E ratio of MCRB?

MCRB trades at a trailing price-to-earnings (P/E) ratio of -2.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.14.

Q: What is the return on equity (ROE) of MCRB?

MCRB has a return on equity (ROE) of -66.57%. Its return on capital employed (ROCE) is -79.05%.

Q: Is MCRB a good stock to buy?

This page provides a data-driven analysis of Seres Therapeutics, Inc. (MCRB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.serestherapeutics.com

Company Profile ↓

$5.56

-65.18% 1Y

Mkt Cap$55.85M

P/E-2.30

P/B1.14

52W High$28.63

52W Low$4.34

Book Value$3.51

EPS (TTM)$-2.42

Company Overview

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Recent Developments

Trailing 12 Months Year-on-year growth — earnings +4088.2%.
5-Year Trend Long-term compounding — revenue CAGR -41.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-41.88%
1 Year:	-

Compounded Profit Growth

5 Years:	-
1 Year:	4,088.24%

Stock Price Performance

1 Year:	-65.18%
6 Months:	-40.34%
3 Months:	-11.46%
1 Month:	+14.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 5% of range

$4.34 $28.63

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)58.51 · Neutral

Price Performance

1M+14.17%

3M-11.46%

6M-40.34%

1Y-65.18%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -41.9% CAGR over 5 years.
Trading 80.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-2.30

Industry PE

24.83

Forward P/E

-1.12

PEG Ratio

Book Value

$3.51

Price to Book

1.14

P/S

21.34

EV/EBITDA

-1.08

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-41.88%

Profit 5Y

Revenue (YoY)

Earnings (YoY)

4,088.24%

Profitability & Returns

ROCE

-79.05%

ROE

-66.57%

ROA

-39.85%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$0.47

EPS (TTM)

$-2.42

Balance Sheet & Liquidity

Debt/Equity

1.64

Quick Ratio

2.04

Current Ratio

2.11

Debt

$56.64M

Total Assets

$101.59M

Current Assets

$49.38M

Working Capital

$30.05M

Ownership

Promoter Holding

11.49%

Chg in Prom Hold

0.01%

FII / Inst Holding

22.99%

Chg in FII Hold

-0.04%

Financial Snapshot

Enterprise Value

$55.85M

Total Revenue (TTM)

$1.88M

EBITDA

$-74.78M

Free Cash Flow

$-64.60M

Operating Cash Flow

$-51.26M

Shares Outstanding

10.04M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MCRB Seres Therapeutics, Inc. PHARMA	5.56	-2.30	$55.85M	0.00%	-79.05%	-66.57%	-41.88%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	3.01M	-	-	3.77M	4.27M	8.68M	-	6.62M	10.45M	4.84M	-	5.46M	5.19M	80.00K	4.65M	5.26M	126.72M	1.49M	1.22M	3.44M	-	-	-	-	-	-	-	0	0	0	789.00K	358.00K	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.53M	1.69M	736.00K	592.00K	0	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.53M	-1.69M	-736.00K	197.00K	358.00K	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.71M	23.19M	21.74M	19.57M	21.27M	-
Operating Income	-14.56M	-19.79M	-19.92M	-28.14M	-19.09M	-25.69M	-25.89M	-28.42M	-7.31M	-29.77M	-28.27M	-28.14M	-22.21M	-21.67M	-24.55M	-10.95M	-17.18M	-19.19M	-19.69M	-20.55M	-30.00M	-35.33M	-48.14M	68.41M	-55.75M	-63.33M	-59.11M	-70.57M	49.52M	-44.59M	-34.44M	-28.87M	-29.17M	-	-27.24M	-24.88M	-22.48M	-19.38M	-20.91M	-21.27M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26.16M	-18.80M	-21.43M	81.24M	-20.13M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32.68M	-19.86M	8.20M	-15.34M	-19.91M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-14.62M	-19.63M	-19.70M	-27.91M	-18.69M	-25.27M	-25.47M	-28.02M	-6.93M	-28.95M	-27.92M	-27.79M	-21.95M	-21.29M	-24.33M	-10.76M	-16.41M	-18.78M	-19.88M	-20.71M	-30.28M	-35.47M	-48.33M	68.22M	-56.62M	-64.73M	-60.00M	-71.17M	46.55M	-47.85M	-40.13M	-32.87M	88.78M	-	32.68M	-19.86M	8.20M	-15.34M	-19.91M	4.58M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.36	-	-0.53	0.72	-0.61	-0.70	-0.49	-0.57	0.36	-0.37	-5.49	-4.34	11.63	-	3.75	-2.27	0.94	-	-2.08	0.47
R&D Expense	9.85M	-	15.42M	22.17M	24.14M	-	20.14M	23.06M	22.21M	-	23.46M	24.05M	23.68M	-	22.89M	17.91M	18.32M	-	21.74M	20.10M	23.86M	29.30M	35.95M	39.88M	39.65M	43.94M	43.12M	43.97M	46.79M	25.15M	19.49M	15.81M	16.46M	-	11.82M	12.94M	12.62M	-	13.20M	9.14M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	21.77M	32.10M	26.92M	27.19M	11.90M	143.86M	7.13M	0	0	789.00K
Operating Income	-6.05M	-15.08M	-54.86M	-92.84M	-91.39M	-100.28M	-71.88M	-88.13M	-64.49M	-179.91M	-195.10M	-121.31M	-93.97M
Net Income	-6.10M	-16.71M	-54.78M	-91.58M	-89.38M	-98.94M	-70.28M	-89.13M	-65.58M	-250.16M	-113.72M	136.00K	5.70M
Diluted EPS	-	-	-	-	-	-	-	-1.12	-0.72	-2.31	-17.77	0.00	0.64
R&D Expense	4.80M	10.72M	38.09M	81.99M	89.45M	95.95M	80.14M	90.57M	141.89M	109.65M	117.60M	64.60M	49.06M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	117.34M	216.90M	272.65M	189.52M	120.47M	132.44M	342.94M	-	348.78M	358.60M	139.81M	138.19M
Current Assets	-	-	-	-	-	-	-	-	-	-	194.76M	175.41M	38.67M	49.38M
Cash & Equivalents	6.21M	1.65M	114.19M	73.93M	54.54M	36.09M	85.82M	65.13M	116.05M	-	163.03M	127.97M	30.79M	45.77M
Inventory	-	-	-	-	-	-	-	-	-	-	0	29.65M	-	-
Receivables	-	-	-	-	-	-	-	-	-	0	-	0	2.07M	517.00K
Total Liabilities	-	-	7.99M	11.51M	140.01M	128.82M	168.52M	180.76M	168.19M	-	338.00M	403.46M	126.03M	93.97M
Current Liabilities	-	-	5.10M	10.92M	30.46M	31.62M	42.04M	45.99M	46.41M	-	85.60M	98.66M	41.22M	19.32M
Long Term Debt	-	-	-	-	-	-	-	25.00M	25.00M	24.64M	50.59M	101.54M	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	162.59M	198.78M	91.64M	82.97M
Total Equity	-4.35M	-11.12M	-26.72M	205.39M	132.63M	60.70M	-48.05M	-48.32M	174.75M	-	10.78M	-44.86M	13.78M	44.22M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	6.26M	6.75M	8.65M	9.56M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	43.92M	-75.52M	-62.85M	-76.52M	-93.61M	6.69M	-228.82M	-117.35M	-148.61M	1.12M
Investing Cash Flow	-	-	-	-65.59M	55.70M	112.32M	-30.52M	-158.89M	64.09M	82.43M	10.58M	142.29M	-42.00K
Financing Cash Flow	-	-	-	2.14M	83.00K	268.00K	86.23M	303.42M	1.18M	129.60M	71.70M	-90.37M	13.90M
Capital Expenditure	-174.00K	-1.00M	-4.36M	-21.49M	-4.68M	-1.94M	-1.00M	-591.00K	-9.57M	-9.82M	-7.97M	-380.00K	-252.00K
Free Cash Flow	-	-	-	22.43M	-80.20M	-64.79M	-77.52M	-94.20M	-2.88M	-238.64M	-125.33M	-148.99M	865.00K
Share Buybacks	-	-	-	-	33.00K	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-426.5%	-284.7%	-372.6%	-264.4%	-740.8%	-44.8%	-2,524.0%	-	-	-11,910.1%
Net Margin %	-	-	-	-420.7%	-278.4%	-367.6%	-258.5%	-749.2%	-45.6%	-3,509.5%	-	-	721.9%
ROE %	54.9%	62.5%	-26.7%	-69.0%	-147.3%	205.9%	145.4%	-51.0%	-	-2,319.9%	253.5%	1.0%	12.9%
ROCE %	-	-13.4%	-26.6%	-38.3%	-57.9%	-127.9%	-83.1%	-29.7%	-	-68.4%	-75.1%	-123.1%	-79.1%

Shareholding Pattern

Insiders

11.49%

Institutions

22.99%

Public Float

25.97%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Flagship Pioneering LLC	11.51%	1.16M	$4.62M
2	Vanguard Capital Management LLC	2.86%	287.78K	$1.15M
3	Marshall Wace LLP	1.71%	172.25K	$688.98K
4	Vontobel Holding Limited	1.22%	122.97K	$491.90K
5	Blackrock Inc.	1.11%	111.00K	$444.00K
6	Geode Capital Management, LLC	0.80%	79.97K	$319.90K
7	Susquehanna International Group, LLP	0.58%	58.33K	$233.31K
8	Vanguard Fiduciary Trust Co	0.48%	48.69K	$194.74K
9	State Street Corporation	0.34%	33.90K	$135.60K
10	Lion Point Capital, LP	0.31%	31.57K	$126.28K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MCRB

Google News ue, 08 Sep 2026

Two new hires get options on 4,200 Seres shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQY3Bmci1EZDZib2t0OW1md3dlVVpqN1N6VEZNTnFsazN2d1E3M3FBdFhGalNySTB6Q01QMmpyWk16OVJhMkkweDdkcjJRY3poczVJWERQMk9BZ3VVRVVRTGU5QlhTZlBMd2tQMlZsZnNJSUNNX0N1N1Zaajc5UmpFMlRRSjJKS1VYcFZzek…

Google News ue, 08 Sep 2026

The Technical Signals Behind (MCRB) That Institutions Follow - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZEttTVVXbXVlN1daTUVsSUdmSm82cldoUTNPcExJZFludWhOMGhwbnM3WVBBUlZuMFpYUXV0NjNOQ0o3b1dnS25walpGSjIyYVgxR1l1YU51eG43djlmbXBwMGNwSXVrQ1RfeF9vbUlTWVNRR2h2dk1FRlVIbVFwNGpvT1paU1pRcmFUdE…

Google News ue, 08 Sep 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOZlpBaDU5QzA5bllla0NaUkxkVWxrclA1dkl3bHE5U0ZXck5aMVBoUEZReV9YTzVKWnRuOFBjOFpwTUFUNEtuRjUtaUVxMU9pczBxcndheWU4bjBlMGJ0MkhYRFFZOTlzMWdCZTRRbjc2VXA2eDZBVVdSTEJ3aU1nd1dDSW5sUU5ZZF9IQk…

Google News Wed, 27 May 2026

MCRB - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0ydURjdTZBLVlWbkdVVG14dUk1d1ZSUnpWaHJpWk9WQVY1TUZGMHNOZFp1ZjdrdTlzZ2tNeWhOZUJ2OVhNVXc?oc=5" target="_blank">MCRB</a>  <font color="#6f6f6f">Finviz</font>…

Google News hu, 05 Mar 2026

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPY2IwM0VMdUVLXzN2YzVLYlJSOVA1UV9RbE5aLU1zYU4xMGZjNVpDZVB0VWdtVlg3eVE5Tk9ybXM3X0FMcEhVRWwtRXVtVE5xNC1iVGJvbHZ2Sm03bmpfSmR6Um02Q05xSi1LZjJDWU1lNkN6bVYxSjZ2Z3Z6SVVNNVh5MXBWc3pJMS00SV…

Google News Sat, 13 Jun 2026

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQWVhJVWQwZnJXeGFtR0lIRXZaa08tUGZJNUR4LThCTDIwSm5rOFRsbkxieGVxRWJXaGtycTVjVDNlNktNMUF1WFlTZFBpTzdzSEVTcERPTDFtYV96SUZxVGxyRU1UOXVlbnFHdC03N1Q2aFRDUWtGSHpMYnYySnN4YUxsWTVzdEwyRUdDc1…

MCRB — Frequently Asked Questions

What is the current share price of Seres Therapeutics, Inc. (MCRB)?

As of 2026-09-19 21:16 PDT, Seres Therapeutics, Inc. (MCRB) trades at $5.56 on NasdaqGS. Its 52-week range is $4.34 to $28.63.

What is the market capitalisation of MCRB?

Seres Therapeutics, Inc. (MCRB) has a market capitalisation of $55.85M on NasdaqGS.

What is the P/E ratio of MCRB?

MCRB trades at a trailing price-to-earnings (P/E) ratio of -2.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.14.

What is the return on equity (ROE) of MCRB?

MCRB has a return on equity (ROE) of -66.57%. Its return on capital employed (ROCE) is -79.05%.

Is MCRB a good stock to buy?

This page provides a data-driven analysis of Seres Therapeutics, Inc. (MCRB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Seres Therapeutics, Inc. MCRB PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Two new hires get options on 4,200 Seres shares - Stock Titan

The Technical Signals Behind (MCRB) That Institutions Follow - Stock Traders Daily

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

MCRB - Finviz

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - finance.yahoo.com

MCRB — Frequently Asked Questions

What is the current share price of Seres Therapeutics, Inc. (MCRB)?

What is the market capitalisation of MCRB?

What is the P/E ratio of MCRB?

What is the return on equity (ROE) of MCRB?

Is MCRB a good stock to buy?

Explore More